Search research articles
Contact Us
Filters
Showing results (1-10 of 53) with videos related to
Page
of 6
Sort By:
Cancer
|
September 27, 2024
Two birds, one stone? The risks and benefits of combined prenatal carrier screening and hereditary cancer screening
Kari L Ring
JAMA Surgery
|
August 14, 2024
The Intersection of Endometriosis and Ovarian Cancer Prevention
Kari L Ring
Current Treatment Options in Oncology
|
November 7, 2018
The Role of PD-1 Checkpoint Inhibition in Gynecologic Malignancies
Christine Garcia, Kari L Ring
Gynecologic Oncology
|
March 31, 2015
One size may not fit all: the debate of universal tumor testing for Lynch syndrome
Karen H Lu, Kari L Ring
Frontiers in Oncology
|
March 20, 2023
Updates in gynecologic care for individuals with lynch syndrome
Kaylee A Underkofler, Kari L Ring
Gynecologic Oncology
|
January 25, 2024
How far is too far? Cancer prevention and clinical trial enrollment in geographically underserved patient populations
Kari L Ring, Linda R Duska
Obstetrics and Gynecology Clinics of North America
|
February 12, 2018
Hereditary Cancers in Gynecology: What Physicians Should Know About Genetic Testing, Screening, and Risk Reduction
Kari L Ring, Susan C Modesitt
Modern Pathology : an Official Journal of the United States and Canadian Academy of Pathology, Inc
|
March 31, 2019
TIM-3 in endometrial carcinomas: an immunotherapeutic target expressed by mismatch repair-deficient and intact cancers
Margaret Moore, Kari L Ring, Anne M Mills
Gynecologic Oncology Reports
|
June 13, 2018
PD-L1 pitfalls: Emphasizing the importance of membranous localization and correlation with tumor cell and macrophage distributions
Anne M Mills, Chelsea Gottlieb, Kari L Ring
Cancer Journal (Sudbury, Mass.)
|
April 26, 2016
Immune Checkpoint Inhibitors in the Treatment of Gynecologic Malignancies
Kari L Ring, Janelle Pakish, Amir A Jazaeri
Page
of 6
Search research articles
Search
Showing results (1-10 of 53) with videos related to
Sort By:
Page
of 6
Cancer
|
September 27, 2024
Two birds, one stone? The risks and benefits of combined prenatal carrier screening and hereditary cancer screening
Kari L Ring
JAMA Surgery
|
August 14, 2024
The Intersection of Endometriosis and Ovarian Cancer Prevention
Kari L Ring
Current Treatment Options in Oncology
|
November 7, 2018
The Role of PD-1 Checkpoint Inhibition in Gynecologic Malignancies
Christine Garcia, Kari L Ring
Gynecologic Oncology
|
March 31, 2015
One size may not fit all: the debate of universal tumor testing for Lynch syndrome
Karen H Lu, Kari L Ring
Frontiers in Oncology
|
March 20, 2023
Updates in gynecologic care for individuals with lynch syndrome
Kaylee A Underkofler, Kari L Ring
Gynecologic Oncology
|
January 25, 2024
How far is too far? Cancer prevention and clinical trial enrollment in geographically underserved patient populations
Kari L Ring, Linda R Duska
Obstetrics and Gynecology Clinics of North America
|
February 12, 2018
Hereditary Cancers in Gynecology: What Physicians Should Know About Genetic Testing, Screening, and Risk Reduction
Kari L Ring, Susan C Modesitt
Modern Pathology : an Official Journal of the United States and Canadian Academy of Pathology, Inc
|
March 31, 2019
TIM-3 in endometrial carcinomas: an immunotherapeutic target expressed by mismatch repair-deficient and intact cancers
Margaret Moore, Kari L Ring, Anne M Mills
Gynecologic Oncology Reports
|
June 13, 2018
PD-L1 pitfalls: Emphasizing the importance of membranous localization and correlation with tumor cell and macrophage distributions
Anne M Mills, Chelsea Gottlieb, Kari L Ring
Cancer Journal (Sudbury, Mass.)
|
April 26, 2016
Immune Checkpoint Inhibitors in the Treatment of Gynecologic Malignancies
Kari L Ring, Janelle Pakish, Amir A Jazaeri
Page
of 6